( January 3, 2024, 1:49 PM EST) -- WASHINGTON, D.C. — Novo Nordisk A/S, the manufacturer of Ozempic, tells the U.S. Judicial Panel for Multidistrict Litigation (JPMDL) that consolidation of cases from consumers who allege that they suffered gastrointestinal and other injuries from diabetes and diet drugs in a multidistrict litigation is proper but argues that the U.S. District Court for the Middle District of North Carolina is a more appropriate venue than the one suggested by the plaintiffs....